Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will be participating in the FBR Second Annual Healthcare Conference on Wednesday, September 9th in Boston. There is no formal presentation during the conference, however, management will be available for one-on-one meetings.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. Synta’s lead oncology drug candidate, ganetespib, a novel heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated in several clinical trials including the pivotal GALAXY-2 Phase 3 trial in non-small cell lung cancer. Building on its extensive expertise in the science of Hsp90, Synta also has a novel proprietary Hsp90 inhibitor Drug Conjugate (HDC) small molecule drug development program. IND enabling studies have commenced for the first clinical candidate from the HDC program, STA-12-8666, and preclinical evaluation of additional HDC candidates is ongoing. For more information, please visit www.syntapharma.com.

Investors:Synta Pharmaceuticals Corp.Daniel Cole, 781-541-7250dcole@syntapharma.comorArgot PartnersAndrea Rabney, 212-600-1494andrea@argotpartners.comorMedia:Argot PartnersEliza Schleifstein, 917-763-8106eliza@argotpartners.com

Grafico Azioni Synta Pharmaceuticals Corp. (MM) (NASDAQ:SNTA)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Synta Pharmaceuticals Corp. (MM)
Grafico Azioni Synta Pharmaceuticals Corp. (MM) (NASDAQ:SNTA)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Synta Pharmaceuticals Corp. (MM)